GO
Loading...

Sanofi SA

More

  • TRENTON, N.J.— Amgen Inc. boosted its first-quarter profit by 51 percent, thanks to surging drug sales and ongoing cost cuts designed to free up cash for an unprecedented burst of new product launches. Amgen reported net income of $1.62 billion, or $2.11 per share, up from $1.07 billion, or $1.40 per share, in 2014' s first quarter. Adjusted net income, excluding...

  • April 7- Denmark's Novo Nordisk A/S said the U.S. Food and Drug Administration accepted a resubmitted application for its key insulin drug, Tresiba, based on interim analysis data from a clinical trial. Tresiba, already available outside the United States, was rebuffed by the FDA two years ago on concerns that the drug could be linked to higher rates of heart...

  • UniQure's shares jumped more than 55 percent on Monday after Bristol-Myers said it would pick up a 4.9 percent stake in the company. UniQure's gene therapy drug, Glyberan, went on sale last year priced at 1.1 million euros. Bayer AG struck a gene therapy deal with Dimension Therapeutics in June, while France's Sanofi SA has a long-standing tie-up with Oxford...

  • *Novo to submit interim trial data for Tresiba with FDA. The drug was rebuffed by the FDA two years ago. Citigroup's Peter Verdult said he believed the odds of U.S. approval were greater than 90 percent, given a small group of Novo staff sitting behind a communications "firewall" had already discussed the data with FDA.

  • March 23- Pfizer Inc and Eli Lilly and Co will resume a late-stage study testing their pain drug tanezumab after the U.S. Food and Drug Administration lifted a partial hold on it. Pfizer expects to receive a $200 million upfront payment from Lilly as a result of the development, the companies said on Monday. In 2013, Pfizer forged a deal with Lilly to jointly develop...

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • PARIS, March 19- Sanofi's lixisenatide drug for the treatment of type 2 diabetes does not increase cardiovascular risk among high risk patients, the French drugmaker said on Thursday. Sanofi was reporting the results of a study it has been waiting to complete before seeking U.S. approval. At the time Sanofi said it would re-submit a U.S. new drug application with...

  • LONDON, March 17- Other big drugmakers may be reshaping their businesses but Novo Nordisk's focus on diabetes will get even bigger in the coming decade, according to the man most likely to be the Danish company's next boss. Kaare Schultz, who was made deputy chief executive in January 2014 and is the frontrunner to eventually succeed 60- year-old Lars Sorensen,...

  • An analysis of about 4,500 patients who stayed on treatment for nearly a year after completing earlier trials of Amgen Inc's Repatha, also known as evolocumab, found that 0.95 percent of those given the drug and standard therapy suffered a cardiovascular event, compared with 2.18 percent of the group on standard treatment, which ranged from diet changes to...

  • An analysis of about 4,500 patients who continued treatment for nearly a year after completing earlier trials of Amgen Inc's Repatha, also known as evolocumab, found that 0.95 percent of patients given the drug and standard therapy suffered a cardiovascular event, compared with 2.18 percent of the group receiving standard treatment, which ranged from...

  • LONDON, March 14- Long-term use of AstraZeneca's drug Brilinta can cut the risk of death, another heart attack or stroke in patients with a history of past attacks by 16 percent, a keenly awaited clinical trial showed on Saturday. The finding may boost sales of the blood-thinner, which AstraZeneca is relying on to drive growth, although doctors must balance its...

  • These cholesterol drugs stocks are poised to move Friday, 13 Mar 2015 | 3:33 PM ET
    Surgeons performing operation

    Here are the stocks to watch heading out of this weekend's American College of Cardiology conference in San Diego.

  • LONDON, March 12- Pfizer is seeking new vaccine opportunities across the age spectrum as it broadens its portfolio by delivering shots into the arms of adolescents and the elderly, as well as infants. For many years the vaccines industry has been dominated by five big companies, but that has shrunk to four with GlaxoSmithKline's purchase of Novartis' business.

  • What!?! Specialty drug spending jumps 31% Tuesday, 10 Mar 2015 | 8:53 AM ET
    Prescription drugs

    Spending on prescription drugs in the U.S. rose 13.1% in 2014, the biggest increase in more than a decade, according a report from Express Scripts.

  • Arrowhead buys Novartis' RNAi portfolio Thursday, 5 Mar 2015 | 7:34 AM ET

    March 5- Arrowhead Research Corp said it acquired Novartis AG's RNAi assets to fortify its position in the field of gene therapy that aims to wipe out disease-causing proteins. Novartis is eligible to receive $25 million in Arrowhead shares within 30 days, which would make it the second-largest shareholder based on Arrowhead's market value on Wednesday.

  • Fighting mosquitoes with more mosquitoes Wednesday, 4 Mar 2015 | 12:09 PM ET
    Mosquito Dengue Fever

    Constant vigilance is the method the Florida Keys has used to ward off mosquito-borne illnesses, but new methods may be on the horizon.

  • Sacked Sanofi boss joins PureTech board Friday, 27 Feb 2015 | 10:08 AM ET

    PARIS, Feb 27- Chris Viehbacher, sacked as chief executive of French drugs firm Sanofi last year, is to join the board of PureTech, a privately owned healthcare science and technology R&D company. Viehbacher, who moved to Boston last year while he was still running Sanofi, raised the French company's multinational profile during his six years in the job by...

  • Feb 26- Sanofi's new Toujeo diabetes drug has won U.S. regulatory approval but with wording on its label that analysts say could make marketing difficult. Sanofi shares were 1 percent lower at 88.20 euros by 1029 GMT. Sanofi bought some time with a patent infringement lawsuit filed last year against Eli Lilly and Co to keep a cheaper Lantus generic off the market...

  • Feb 23- Eli Lilly and Co said it would postpone by at least two years the marketing application for its once-daily diabetes treatment to evaluate liver concerns, a delay some analysts said could doom the experimental drug. In the meantime, Lilly continues to develop a cheaper, rival "biosimilar" form of Sanofi's blockbuster once-daily Lantus insulin that...